Screener
Kymera Therapeutics KYMR Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -333.5%+364pp | -697.7%-225pp | -891.1%-335pp | -759.7%-531pp | -697.5%-488pp | |
| Net margin | -285.3%+331pp | -612%-203pp | -794.1%-318pp | -674.8%-484pp | -616%-438pp | |
| Returns | ||||||
| Return on equity | -24.2%+9.1pp | -27.1%+5.1pp | -25.8%+10.6pp | -32.1%-6.1pp | -33.3%-5.1pp | |
| Return on invested capital | -32%+11.6pp | -31.8%+5.6pp | -33.1%+11.4pp | -37.1%-5.5pp | -43.6%-11.8pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×-0.1× | 0×-0.1× | |
| Liquidity | ||||||
| Current ratio | 10.3×+2.0× | 10.8×+2.3× | 10.5×+2.9× | 7.4×-1.2× | 8.3×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×-0.1× | 0.1×-0.1× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $15.37+27.3% | $15.79+60.9% | $18.70+67.9% | $10.84-7.6% | $12.08+28.8% | |
| Valuation | ||||||
| Market capitalization | $8.68B+199% | $6.8B+283% | $6.22B+139% | $4.05B+12.3% | $3.07B+40.8% | |
| Price / sales | 82.6×+17.8× | 132.1×+102× | 158.8×+103× | 92.5×+51.4× | 68.7×+44.0× | |
| Price / book | 5.7×+2.8× | 4.4×+2.2× | 3.9×+0.8× | 4.3×+0.2× | 3.2×0.0× |
FAQ
- Where do Kymera Therapeutics's ratios come from?
- Every ratio is computed from Kymera Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
